The collaboration combines SOPHiA’s DDM platform with Element’s AVITI sequencing systems to streamline genomic workflows for precision medicine research.
SOPHiA GENETICS and Element Biosciences have announced a partnership that integrates AI-powered analytics with next-generation sequencing (NGS) systems to accelerate genomic research workflows.
The collaboration, announced at the Association for Molecular Pathology Annual Meeting, combines SOPHiA GENETICS’ AI-driven analytics platform, SOPHiA DDM, with Element’s AVITI24 5D multiomic and AVITI sequencing systems. The integration aims to provide laboratories with an end-to-end workflow that turns NGS data into actionable insights within a single streamlined process.
AVITI and AVITI24 users will gain access to the full suite of SOPHiA DDM applications in oncology and rare disease, expanding the analytical capabilities of their sequencing workflows.
“We believe that combining the Element AVITI system with the SOPHiA DDM Platform has the potential to change the way our lab approaches genomic testing by seamlessly delivering highly accurate results,” says Hagay Sobol, head of the Molecular Oncogenetics Laboratory at the Institut Paoli-Calmettes (IPC), in a release. “We expect this collaboration that pairs SOPHiA GENETICS’ powerful analytics with Element’s sequencing performance will be able to deliver the consistency and scalability needed for research that helps bring precision medicine to more patients, faster.”
IPC is a cancer center in Marseille, France, specializing in cancer research, treatment, and teaching.
Technology Integration Details
SOPHiA DDM is a technology-agnostic analytics platform that uses AI to compute, standardize, and analyze healthcare data. Through this partnership, laboratories can process datasets of any size while retaining full control of their data and scaling efficiently as precision medicine adoption increases, according to a release from the company.
Element Biosciences‘ AVITI24 5D Multiomic and AVITI NGS systems are designed to make high-performance genomics accessible with accuracy, flexibility, and cost efficiency.
“Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local,” says Jurgi Camblong, CEO and co-founder of SOPHiA GENETICS, in a release. “This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies.”
Molly He, CEO and co-founder of Element Biosciences, adds in a release, “Pairing Element’s cutting-edge AVITI and AVITI24 systems with SOPHiA GENETICS’ powerful AI analytics is a game-changer for the genomics community. This collaboration doesn’t just streamline workflows; it redefines what’s possible in sequencing, delivering richer insights, faster results, and unprecedented accessibility.”
ID 255405677 © Yuri Arcurs | Dreamstime.com
